STABLE INSULIN FORMULATIONS AND METHODS OF MAKING AND USING THEREOF

• US 20140024582A1
• Filed: 03/21/2013
• Published: 01/23/2014
• Est. Priority Date: 01/11/2010
• Status: Abandoned Application

• Current Assignee: Guohan Yang
• Original Assignee: GeneCopoeia, Inc.
• Inventors: YANG, Guohan
• Application Number:
  US13/848,617
• Publication Number:
  US 20140024582A1
• Time in Patent Office: Days
• US Class Current: 514/6.4
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/183 Amino acids, e.g. glycine, EDTA or aspartame
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

The invention provides methods for improving the physical and chemical stabilities of therapeutic proteins in solutions by reducing or eliminating protein degradation, aggregation and precipitation using small molecule stabilizing agents such as proline, arginine and/or compounds capable of forming a Schiff bond with amino groups of the protein. The invention further provides liquid formulations of a monomeric insulin stabilized by one of more stabilizing agents such as proline, arginine and/or acetone. Also provided are methods of making and using the stabilized monomeric insulin formulations.

Claims

1. A composition comprising a monomeric insulin and proline or a proline derivative, wherein the composition is in a liquid form.

2. The composition of claim 1, wherein the insulin is a human insulin, a porcine insulin, a bovine insulin, an insulin analog, an insulin derivative, or a combination thereof.

11. The composition of claim 1, further comprising a stabilizing agent which is a compound capable of forming a Schiff bond with an amino group.

12. The composition of claim 11, wherein the stabilizing agent is selected from the group consisting of acetone, pyruvic acid, glyoxalic acid, alpha-ketobutyric acid, alpha-ketoglutaric acid, acetoacetic acid, pyridoxal, and pyridoxal pyrophosphate.

15. The composition of claim 1, further comprising a pharmaceutically acceptable excipient.

16. The composition of claim 15, wherein the pharmaceutically acceptable excipient is glycerol and/or a phenolic compound.

3. The composition of claim 1, wherein the insulin is a zinc-free human insulin, a zinc-free porcine insulin, a zinc-free bovine insulin, a zinc-free insulin analog, a zinc-free insulin derivative, or a combination thereof.

3-1. (canceled)

4-10. -10. (canceled)

13-14. -14. (canceled)

17-20. -20. (canceled)

21. The composition of claim , wherein the pH range of the liquid is between about 6.0 and about 8.0.

22-24. -24. (canceled)

25. A composition comprising a monomeric insulin and arginine, wherein the composition is in a liquid form.

26. (canceled)

27. A method of making a stable monomeric insulin composition comprising:

(a) mixing a zinc insulin in a solution with a zinc chelating reagent, wherein the molar ratio of the zinc chelating reagent to zinc is from about 1;

1 to about 100;

1; and

(b) adding proline, a proline derivative, and/or arginine to the solution formed in step (a) to form a stabilized insulin solution.

30. The method of claim 27, wherein the zinc insulin is selected from the group consisting of a zinc human insulin, a zinc porcine insulin, a zinc bovine insulin, a zinc insulin analog, a zinc insulin derivative, and a combination thereof.

34. The method of claim 27, further comprising adding a stabilizing agent to the solution formed in step (a) or the stabilized insulin solution.

38. The method of claim 27, further comprising adding a pharmaceutically acceptable excipient to solution formed in step (a) or the stabilized insulin solution.

44. A stable monomeric insulin composition made by the method of claim 27.

28-29. -29. (canceled)

35-37. -37. (canceled)

39-43. -43. (canceled)

45-75. -75. (canceled)

76. A method for stabilizing a protein in solution comprising mixing the protein in solution with one or more small molecule excipients, wherein the one or more small molecule excipient comprise praline or a praline derivative at a concentration of about 0.9 mon to about 7.0 moll,.

77-88. -88. (canceled)